12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

WX-037: Phase I started

In its 6-month financial report for the period ending May 31, Wilex said it began in July an open-label, dose-escalation, U.K. Phase I trial of WX-037 alone and in...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >